JP2006515004A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006515004A5 JP2006515004A5 JP2005518422A JP2005518422A JP2006515004A5 JP 2006515004 A5 JP2006515004 A5 JP 2006515004A5 JP 2005518422 A JP2005518422 A JP 2005518422A JP 2005518422 A JP2005518422 A JP 2005518422A JP 2006515004 A5 JP2006515004 A5 JP 2006515004A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- formula
- pharmaceutically acceptable
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 claims 2
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 150000002825 nitriles Chemical class 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- XHSXSBMPWKBHJC-UHFFFAOYSA-N 3-(1h-indol-3-yl)-4-[6-(4-methylpiperazin-1-yl)-3-(trifluoromethyl)pyridin-2-yl]pyrrole-2,5-dione Chemical compound C1CN(C)CCN1C1=CC=C(C(F)(F)F)C(C=2C(NC(=O)C=2C=2C3=CC=CC=C3NC=2)=O)=N1 XHSXSBMPWKBHJC-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 238000003556 assay Methods 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 102000015766 Protein Kinase C beta Human genes 0.000 description 1
- 108010024526 Protein Kinase C beta Proteins 0.000 description 1
- 102000014458 Protein Kinase C-epsilon Human genes 0.000 description 1
- 108010078137 Protein Kinase C-epsilon Proteins 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid group Chemical group C(CCCCC)(=O)O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- -1 hydrochloric acid Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0303319.8A GB0303319D0 (en) | 2003-02-13 | 2003-02-13 | Organic compounds |
| PCT/EP2004/001323 WO2004072062A2 (en) | 2003-02-13 | 2004-02-12 | Indolylmaleimide derivatives |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009165725A Division JP2009280592A (ja) | 2003-02-13 | 2009-07-14 | インドリルマレイミド誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006515004A JP2006515004A (ja) | 2006-05-18 |
| JP2006515004A5 true JP2006515004A5 (enExample) | 2009-09-03 |
Family
ID=9952961
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005518422A Ceased JP2006515004A (ja) | 2003-02-13 | 2004-02-12 | インドリルマレイミド誘導体 |
| JP2009165725A Pending JP2009280592A (ja) | 2003-02-13 | 2009-07-14 | インドリルマレイミド誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009165725A Pending JP2009280592A (ja) | 2003-02-13 | 2009-07-14 | インドリルマレイミド誘導体 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7820672B2 (enExample) |
| EP (2) | EP2075249B1 (enExample) |
| JP (2) | JP2006515004A (enExample) |
| CN (1) | CN100439359C (enExample) |
| AT (2) | ATE463491T1 (enExample) |
| BR (1) | BRPI0407512A (enExample) |
| CA (1) | CA2513613A1 (enExample) |
| DE (1) | DE602004026415D1 (enExample) |
| ES (2) | ES2385071T3 (enExample) |
| GB (1) | GB0303319D0 (enExample) |
| PT (1) | PT1597250E (enExample) |
| WO (1) | WO2004072062A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2246346B1 (en) * | 2005-07-11 | 2012-10-24 | Novartis AG | Indolylmaleimide derivatives as protein kinase inhibitors |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス，インコーポレイティド | ムスカリン性受容体調節による神経発生 |
| JP2009512711A (ja) | 2005-10-21 | 2009-03-26 | ブレインセルス，インコーポレイティド | Ｐｄｅ阻害による神経新生の調節 |
| EP2314289A1 (en) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| AU2007249399A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| KR20090100363A (ko) | 2006-12-19 | 2009-09-23 | 노파르티스 아게 | 키나제 억제제로서의 인돌릴말레이미드 유도체 |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| CN101671329B (zh) * | 2009-06-17 | 2012-11-07 | 东华大学 | 3-氨基醇取代的吲哚马来酰亚胺化合物、其制备和应用 |
| WO2014090398A1 (en) * | 2012-12-10 | 2014-06-19 | Centogene Ag | Use of maleimide derivatives for preventing and treating leukemia |
| CN104693198B (zh) * | 2014-12-13 | 2017-03-08 | 浙江工业大学 | 3‑(1,2,4‑三氮唑并[4,3‑a]吡啶‑3‑基)‑4‑(1H‑吲哚‑3‑基)马来酰亚胺类衍生物及其制备方法和应用 |
| PH12017502013B1 (en) | 2015-05-07 | 2022-07-22 | Agenus Inc | Anti-ox40 antibodies and methods of use thereof |
| SG10201912984WA (en) | 2015-12-02 | 2020-03-30 | Agenus Inc | Antibodies and methods of use thereof |
| EP3538152A4 (en) | 2016-11-09 | 2020-09-30 | Agenus Inc. | ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE |
| WO2018132636A1 (en) * | 2017-01-12 | 2018-07-19 | The Research Foundation For The State University Of New York | [18f]maleimide-based glycogen synthase kinase-3beta ligands for positron emission tomography imaging and radiosynthesis method |
| CN110551103B (zh) * | 2018-05-30 | 2022-08-23 | 北京大学深圳研究生院 | 一种jak3选择性抑制剂 |
| US20220133740A1 (en) | 2019-02-08 | 2022-05-05 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0629947B2 (ja) | 1986-07-16 | 1994-04-20 | 正浩 入江 | 光学記録材料 |
| SK75289A3 (en) * | 1988-02-10 | 1998-05-06 | Hoffmann La Roche | Substituted pyrroles, their use for producing a drug, and the drug on their base |
| DE4005970A1 (de) | 1990-02-26 | 1991-08-29 | Boehringer Mannheim Gmbh | Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten |
| GB9123396D0 (en) | 1991-11-04 | 1991-12-18 | Hoffmann La Roche | A process for the manufacture of substituted maleimides |
| JPH07504673A (ja) | 1992-03-20 | 1995-05-25 | ザ・ウエルカム・ファウンデーション・リミテッド | 抗ウイルス活性を有するインドール誘導体 |
| JPH06161024A (ja) | 1992-11-26 | 1994-06-07 | Sanyo Electric Co Ltd | 光学記録材料 |
| US5405864A (en) | 1993-10-15 | 1995-04-11 | Syntex (U.S.A.) Inc. | Chemotherapeutic maleimides |
| US5559228A (en) | 1995-03-30 | 1996-09-24 | Eli Lilly And Company | Synthesis of bisindolylmaleimides |
| JPH0961647A (ja) | 1995-08-25 | 1997-03-07 | Nippon Telegr & Teleph Corp <Ntt> | 光素子用有機材料 |
| FR2772266B1 (fr) | 1997-12-12 | 2000-02-04 | Oreal | Utilisation d'agent de coloration photochrome dans une composition cosmetique, et composition cosmetique le comprenant |
| WO2000021927A2 (en) | 1998-10-08 | 2000-04-20 | Smithkline Beecham Plc | Pyrrole-2,5-diones as gsk-3 inhibitors |
| GB9828640D0 (en) | 1998-12-23 | 1999-02-17 | Smithkline Beecham Plc | Novel method and compounds |
| US6359150B1 (en) | 1999-08-31 | 2002-03-19 | Kyocera Corporation | Photochromic compound and optical function device using the same |
| WO2001030331A2 (en) | 1999-10-22 | 2001-05-03 | Eli Lilly And Company | Therapeutic compositions including protein kinase c inhibitors |
| US6281356B1 (en) | 1999-12-22 | 2001-08-28 | Hoffmann-La Roche Inc. | Substituted pyrroles |
| DE60129222T2 (de) | 2000-05-11 | 2008-03-06 | Consejo Superior de Investigaciónes Científicas | Heterocyclischen inhibitoren von glycogen synthase kinase gsk-3 |
| ES2233691T3 (es) | 2000-07-27 | 2005-06-16 | F. Hoffmann-La Roche Ag | Derivados de 3-indolil-4-fenil-1h-pirrol-2,5-diona como inhibidores de la glicogen sintasa kinasa-3beta. |
| ES2332770T3 (es) | 2000-11-07 | 2010-02-12 | Novartis Ag | Derivados de indolilmaleimida como inhibidores de la proteina quinasa c. |
| JP2002285146A (ja) | 2001-03-27 | 2002-10-03 | Masahiro Irie | フォトクロミック組成物及び線量計 |
| EP1373494B1 (en) | 2001-03-29 | 2006-03-01 | Topo Target A/S | Succinimide and maleimide derivatives and their use as topoisomerase ii catalytic inhibitors |
| BE1014306A6 (fr) | 2001-07-19 | 2003-08-05 | Project 21C | Dispositif de stationnement d'un cycle avec antivol. |
| IL163777A0 (en) | 2002-03-08 | 2005-12-18 | Lilly Co Eli | Kinase inhibitors |
| PE20040079A1 (es) * | 2002-04-03 | 2004-04-19 | Novartis Ag | Derivados de indolilmaleimida |
-
2003
- 2003-02-13 GB GBGB0303319.8A patent/GB0303319D0/en not_active Ceased
-
2004
- 2004-02-12 AT AT04710393T patent/ATE463491T1/de active
- 2004-02-12 EP EP09004073A patent/EP2075249B1/en not_active Expired - Lifetime
- 2004-02-12 JP JP2005518422A patent/JP2006515004A/ja not_active Ceased
- 2004-02-12 ES ES09004073T patent/ES2385071T3/es not_active Expired - Lifetime
- 2004-02-12 EP EP04710393A patent/EP1597250B8/en not_active Expired - Lifetime
- 2004-02-12 DE DE602004026415T patent/DE602004026415D1/de not_active Expired - Lifetime
- 2004-02-12 CN CNB2004800029076A patent/CN100439359C/zh not_active Expired - Fee Related
- 2004-02-12 ES ES04710393T patent/ES2343115T3/es not_active Expired - Lifetime
- 2004-02-12 BR BRPI0407512-9A patent/BRPI0407512A/pt not_active IP Right Cessation
- 2004-02-12 US US10/542,175 patent/US7820672B2/en not_active Expired - Fee Related
- 2004-02-12 AT AT09004073T patent/ATE551335T1/de active
- 2004-02-12 PT PT04710393T patent/PT1597250E/pt unknown
- 2004-02-12 CA CA002513613A patent/CA2513613A1/en not_active Abandoned
- 2004-02-12 WO PCT/EP2004/001323 patent/WO2004072062A2/en not_active Ceased
-
2009
- 2009-07-14 JP JP2009165725A patent/JP2009280592A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006515004A5 (enExample) | ||
| EP2429986B1 (en) | Haloalkyl heteroaryl benzamide compounds | |
| EP2877457B1 (en) | Cystathionine-gamma-lyase (cse) inhibitors | |
| JP4792025B2 (ja) | ５−ヒドロキシインドール−３−カルボン酸エステル類誘導体およびその用途 | |
| JP6021805B2 (ja) | 腫瘍治療剤 | |
| JP2006523216A5 (enExample) | ||
| WO2007139150A1 (ja) | ＴＮＦα阻害物質を含有してなる抗インフルエンザウイルス剤 | |
| JP2005506368A (ja) | 肥満の処置におけるまたは食物摂取の減少のためのインドールおよびインドリン誘導体の使用 | |
| WO2019046287A1 (en) | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HEPATITIS B | |
| US20200323828A1 (en) | Methods of treating behavior alterations | |
| CN100361975C (zh) | 5－羟基－3－羧酸酯吲哚类衍生物及其制备方法 | |
| JP4034849B2 (ja) | 慢性腺維形成性肝疾患、急性肝疾患およびそれに関わる合併症の治療および予防のための非ペプチドブラジキニン拮抗剤の使用 | |
| US6455567B1 (en) | Method of treatment | |
| HUP0002966A2 (hu) | Alfa-2-adrenoreceptor agonistákként alkalmazható [(2-imidazolidinilidén)-amino]-benzoxazol-származékok és az ezeket tartalmazó gyógyszerkészítmények | |
| JP2007507472A5 (enExample) | ||
| CN101663035B (zh) | 4-环丙基甲氧基-n-(3，5-二氯代-1-氧化-吡啶-4-基)-5-(甲氧基)吡啶-2-甲酰胺在制备用于治疗与帕金森症有关的运动障碍的药物中的用途 | |
| JP2019535680A (ja) | キナーゼを阻害する組成物及び方法 | |
| US20070004777A1 (en) | Methods for treating or preventing acute myelogenous leukemia | |
| CN100584828C (zh) | 新的5-羟基吲哚-3-羧酸酯类衍生物 | |
| CN101663036B (zh) | 4-环丙基甲氧基-n-(3,5-二氯代-1-氧代-4-吡啶-4-基)-5-(甲氧基)吡啶-2-甲酰胺用于治疗颅脑创伤的用途 | |
| CN113631164A (zh) | 使用kdm1a抑制剂如化合物伐菲德司他治疗注意缺陷多动症的方法 | |
| US20190231732A1 (en) | Compositions and methods for stimulating ventilatory and/or respiratory drive | |
| CN100519523C (zh) | 5-羟基吲哚-3-羧酸酯类衍生物及其用途 | |
| JP2004002272A (ja) | ２型糖尿病治療剤 | |
| CN105102428B (zh) | 新型dpp-iv抑制剂 |